These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 30419345)

  • 41. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
    James N; Owusu E; Rivera G; Bandyopadhyay D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Research progress on immunotherapy in triple‑negative breast cancer (Review).
    Zhang X; Ge X; Jiang T; Yang R; Li S
    Int J Oncol; 2022 Aug; 61(2):. PubMed ID: 35762339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
    Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA
    Breast J; 2015; 21(6):627-33. PubMed ID: 26547900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted approaches to triple-negative breast cancer: current practice and future directions.
    Brunello A; Borgato L; Basso U; Lumachi F; Zagonel V
    Curr Med Chem; 2013; 20(5):605-12. PubMed ID: 23278396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
    Michaels E; Chen N; Nanda R
    Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.
    Khadela A; Soni S; Megha K; Shah AC; Pandya AJ; Kothari N; Shah I; Avinash CB
    Med Oncol; 2022 Dec; 40(1):48. PubMed ID: 36520261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
    Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
    Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
    Zhou Y; Che Y; Fu Z; Zhang H; Wu H
    Front Public Health; 2022; 10():902378. PubMed ID: 35875026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers.
    Abd El-Hafez A; Shawky Mohamed Ael-A; Elesawy BH
    Asian Pac J Cancer Prev; 2013; 14(2):1037-41. PubMed ID: 23621182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer.
    Islam R; Lam KW
    Eur J Med Chem; 2020 Dec; 207():112812. PubMed ID: 32937283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triple-negative breast cancer survival in Iranian patients.
    Aghili M; Lashkari M; Farrokhpey AH; Izadi S
    Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
    Geng P; Chi Y; Yuan Y; Yang M; Zhao X; Liu Z; Liu G; Liu Y; Zhu L; Wang S
    Front Cell Dev Biol; 2023; 11():1158539. PubMed ID: 37457288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.